The predictive value of IncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

Chao Tu1,2, Xiaolei Ren1,2, Jieyu He3, Shuangqing Li1,2, Lin Qi1,2, Zhixi Duan1,2, Wanchun Wang1,2 and Zhihong Li1,2*

Abstract

Background: Emerging studies have explored the prognostic value of MIR31HG in cancers, but its role remains elusive. Herein, we aimed to summarize the prognostic potential of MIR31HG in this study.

Methods: Several databases were searched for literature retrieval on Dec 5, 2019. Overall and subgroup analyses were conducted to measure the relationship between MIR31HG expression and clinical outcomes. Moreover, GEPIA was applied for validation of prognostic value of MIR31HG in tumor patients in TCGA dataset.

Results: Overall, seventeen studies with 2573 patients were enrolled. Compared to counterparts, those patients with high MIR31HG expression tended to have shorter RFS. Notably, MIR31HG overexpression predicted unfavorable OS in lung cancer. By contrast, gastrointestinal cancer patients with elevated MIR31HG expression predicted better OS and disease-free survival. Additionally, MIR31HG overexpression was significantly associated with worse clinicopathological features including advanced tumor stage and LNM in lung cancer, but favorable clinical characteristics in gastrointestinal cancer. Moreover, the positive association between MIR31HG and OS in lung cancer was further confirmed in TCGA dataset.

Conclusion: Overexpression of MIR31HG suggested remarkable association with poor prognosis in terms of OS, tumor stage, and LNM in lung cancer, but favorable prognosis in gastrointestinal cancer. Therefore, MIR31HG may serve as a promising prognostic biomarker in multiple cancers.

Keywords: LncRNA MIR31HG, Sarcoma, Tumor, Prognosis, Overall survival

Background

Cancer is the major cause of death and public health problem worldwide [1]. In spite of notable continuous advances in cancer treatment over the last decades, the patients’ survival rate remains disappointed [2]. Nowadays, only a minority of patients in early clinical stage could benefit from curative approaches, while the rest patients, particularly those with advanced stage, may be resistant to conventional treatments [3]. Against this backdrop, it is necessary to explore reliable biomarkers harboring sufficient sensitivity and specificity for early diagnosis and attractive targets for therapeutic intervention before reaching to advanced stages [4, 5].

Long non-coding RNAs (lncRNAs), longer than 200 nucleotides (nt), are defined as highly conserved non-coding RNAs with limited or no protein-coding capacity [6]. lncRNA are involved in diverse physiological and pathological cellular processes [7] by promoting or restraining the protein-coding genes expression [8]. Accumulating evidences have showed that aberrant
expression of lncRNA could drive tumor phenotypes, including initiation, invasion, and metastasis, via interacting with other cellular macromolecules [9]. More recently, emerging lncRNAs have been identified and characterized as crucial factors in tumorigenesis, with certain reports highlighting them as biomarkers and targets in various cancers, such as breast cancer anti-estrogen resistance 4 (BCAR4) [10], small nucleolar RNA host gene 16 (SNHG16) [11], and TTN antisense RNA 1 (TTN-AS1) [12].

LncRNA microRNA-31 host gene (MIR31HG), also known as LOC554202 [13], is a newly identified lncRNA with a length of 2166 nt [2, 4]. Meanwhile, MIR31HG was also named as LncHIFCAR (long noncoding HIF-1α co-activating RNA) since it is a hypoxia-inducible lncRNA [4]. P16 (INK4A) is a well-known tumor suppressor, MIR31HG was reported to negatively regulate p16-dependent senescence phenotype [14], suggesting a potential role in carcinogenesis.

Recently, an increasing number of studies have been exploring the prognostic association between MIR31HG and cancers. Abnormal expression of MIR31HG has been reported in a diverse range of cancer types, including osteosarcoma [15], chordoma [16], colorectal cancer (CRC) [17–19], hepatocellular carcinoma (HCC) [6], lung cancer [2, 20–24], gastric cancer [25], bladder cancer [26], pancreatic ductal adenocarcinoma (PDAC) [7], oral squamous cell carcinoma (OSCC) [4], breast cancer [13, 27], cervical cancer [28], vulvar squamous cell carcinoma (VSCC) [29], and esophageal squamous cell carcinoma (ESCC) [30, 31]. Furthermore, MIR31HG expression was remarkably associated with survival time, tumor-node metastasis (TNM) stage and carcinogenesis of certain cancers. However, the prognostic significance of MIR31HG may be jeopardized by controversial results, ethnic or geographical limitations, and limited sample size. For example, Sun et al. [30] reported that MIR31HG expression was significantly elevated in ESCC tissues and plasma, and MIR31HG could promote ESCC cell proliferation, migration and invasion [30]. On the contrary, another study revealed that MIR31HG appeared to have lower expression in ESCC tissues and patients with reduced MIR31HG were correlated with malignant clinical features. The contradictory expression patterns of MIR31HG were also found in breast cancer [15, 27], CRC [19, 32, 33] and gastric cancer [25, 34]. In view of these conflicting data, for the first time, we performed this comprehensive meta-analysis of the current evidences in order to determine the predictive value of MIR31HG in various carcinomas.

Materials and methods

Literature search strategy

Studies in relevant with MIR31HG and cancer prognosis were thoroughly searched via PubMed, Web of Science, and Cochrane library (up to Dec 5, 2019). The search strategy was used as following: (“Cancer” OR “Malignancy” OR “Sarcoma” OR “Tumor” OR “Neoplasm” OR “Carcinoma”) AND (“MIR31HG” OR “LOC554202” OR “LncHIFCAR”) AND (“Long non-coding RNA” OR “LncRNA” OR “long untranslated RNA”OR “lincRNA”) AND (“Prognosis” OR “Prognostic”). The reference lists of enrolled studies were further reviewed to identify relevant articles.

Study selection criteria and data extraction

Studies were included based on the following inclusion criteria: [1] original studies; [2] the diagnosis of cancer was validated by pathology and histology; [3] studies exploring the correlation between MIR31HG and cancers; [4] MIR31HG expression levels were measured and divided into high or low expression group; [5] reporting of at least one of the endpoints: overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS), et al.; [6] sufficient data: the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) or K-M survival curves were shown; [7] the more recent article was selected if duplicated researches were reported.

On contrary, studies were excluded due to following exclusion criteria: [1] article type: meta-analysis, reviews, editorial material, or case reports; [2] in vivo or in vitro studies without clinical data; [3] sufficient survival data were not provided or cannot be extracted; [4] full text was not accessible; [5] duplicates.

Two independent investigators (CT and XLR) screened and extracted the data from selected studies according to the criteria abovementioned. Any divergence views were resolved by another senior researcher (WCW) to reach a consensus. The following items were provided: first author, year of publication, country, sample size, tumor type, detection methods, follow-up time, and prognostic outcomes. HRs (ORs) and 95% CIs were obtained from the original texts in eligible studies as provided. If not, Engauge Digitizer (version 4.1) would be used to calculate the HR through K-M survival curve as previously described [11].

Quality assessment

Two investigators (JYH and SQL) assessed the quality of studies independently in accordance with the Newcastle–Ottawa scale (NOS). Usually, studies with
NOS ≥ 6 were considered as high-quality. The scores of all eligible studies in this study ranged from 6 to 8, which indicated high quality.

Prognosis analysis in GEPIA using TCGA dataset
Gene Expression Profiling Interactive Analysis (GEPIA) (http://geopia.cancer-pku.cn/index.html) based on The Cancer Genome Atlas (TCGA) data [35] was further searched for cross-validation of the expression pattern and prognostic significance of MIR31HG in cancers.

Publication bias and sensitivity analysis
Sensitivity analysis was performed by omitting individual study consecutively to evaluate their impact on this study. Begg’s test and Egger’s test were both utilized to evaluate the publication bias.

Statistical analysis
Data analysis was conducted by using STATA (version 12.0) and RevMan (Version 5.3). A two-tailed P value less than 0.05 was considered statistically significant. HRs and corresponding 95% CIs were adopted to evaluate the relation between MIR31HG expression and cancer prognosis as well as other clinicopathological characteristics. Heterogeneity of the included studies was assessed by Cochrane’s Q statistic and $I^2$ test. If $p<0.05$, or $I^2 \geq 50\%$, a random-effects model shall be applied to calculate the pooled results due to substantial heterogeneity. Otherwise, a fixed-effects model would be used. Subgroup analysis was performed as per the tumor type and follow-up months in case of obvious heterogeneity among the selected studies.

Results
Characteristics of the included studies
According to the screening criteria, seventeen articles comprising 2573 patients were included in our study [1, 2, 4, 6, 15, 17, 19, 23, 25, 26, 28–33, 36]. All the included studies were related to lncRNA MIR31HG in cancer and comprised clinical data. The study screening flow diagram was shown in Fig. 1. Among the included seventeen articles, twelve types of cancers were identified, including osteosarcoma, cervical cancer, gastric cancer, bladder cancer, CRC, lung adenocarcinoma (LUAD), non-small-cell lung carcinoma (NSCLC), HCC, VSCC, ESCC, OSCC, and laryngeal squamous cell carcinoma (LSCC). The included studies were performed between 2015 and 2019, and almost all of them were originated in China except one from Norway [17]. The sample size ranged from 16 to 1265. Survival analysis regarding OS, DFS and RFS were measured in twelve studies with follow-up time ranging from 25 to 100 months. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was utilized for analysis of the relative expression level of MIR31HG in tumor tissues except one used RNA sequencing [4]. The cut-off values of MIR31HG expression were median value. NOS scores were calculated for the quality evaluation with value ranging from 6 to 8, indicating that the enrolled studies were of high quality. Details of the abovementioned characteristics of the studies were presented in Table 1.

Expression of lncRNA MIR31HG as a prognosis marker in various cancers
In this study, the association between prognosis and MIR31HG expression were reported in twelve studies. Eleven studies were included for OS meta-analysis. As the result of meta-analysis exhibited obvious heterogeneity (P < 0.001, $I^2 = 88.1\%$), subgroup analysis was further conducted to calculate the pooled HRs or ORs and 95% CIs in which the patients were stratified by cancer type (gastrointestinal cancer, lung cancer or others), or follow-up time (more or less than 50 months), as shown in Fig. 2a and Additional file 1: Figure S1, respectively. The gastrointestinal cancer included ESCC, gastric cancer, HCC, and CRC, while the lung cancer consisted of NSCLC and LUAD. Besides, OSCC, LSCC and cervical cancer were grouped in other cancers. The random-effect model was applied to reduce the possible bias. All the pooled HRs and 95% CIs of the overall and subgroup analysis were shown in Table 2. The results demonstrated that elevated expression of the MIR31HG predicted favorable OS in gastrointestinal cancer (HR = 0.56, 95% CI 0.41–0.77), but unfavorable OS in lung cancer (HR = 1.64, 95% CI 1.15–2.34) and other cancers (HR = 3.37, 95% CI 2.69–4.23) (Fig. 2a and Table 2). Interestingly, the pooled results also showed that overexpression of MIR31HG predicted shorter OS in studies with follow-up months less than 50, while no correlation was found in studies with follow-up more than 50 months (Figure S1A).

Moreover, two studies on CRC for DFS and three studies on various cancers reported available data for RFS were further pooled for measurement. The HR and 95% CI (HR = 0.44, 95% CI 0.27–0.72) indicated overexpression of MIR31HG predicted favorable DFS in CRC (Fig. 2b). However, overexpression of MIR31HG was correlated with poor RFS (HR = 2.54, 95% CI 1.91–3.38) (Fig. 2c).

Association between MIR31HG expression and other clinicopathologic parameters
The association between MIR31HG and clinicopathologic features, including clinical stage, lymph node metastasis (LNM), distant metastasis (DM), and tumor size were further analyzed by ORs and their 95% CIs. There was no significant difference in MIR31HG expression detected in DM (OR = 0.75, 95% CI 0.31–1.85) and
tumor size (OR = 0.95, 95% CI 0.581.56), even if the stratified analysis were performed by cancer type (Fig. 3a, b). Although, the pooled overall OR and 95% CI showed no significant difference in MIR31HG expression analysis in various clinical stage (OR = 1.41, 95% CI 0.772.56) and LNM (OR = 1.65, 95% CI 0.932.91), after subgroups analysis by cancer type, the results suggested that upregulated expression of MIR31HG indicated the advanced clinical stage (OR = 6.26, 95% CI 3.5311.11) and higher risk of LNM in lung cancer (OR = 2.08, 95% CI 1.044.15) (Fig. 3c, d).

**Sensitivity analysis**
Sensitivity analysis was performed to the studies which had more than two articles. All results showed that this meta-analysis was stable except the analysis of clinical stage (Fig. 4a) and LNM (Fig. 4b). After dropping the research performed by Sun et al., the pooled ORs and 95% CIs showed that elevated expression of MIR31HG were negatively associated with clinical stage (OR = 0.30, 95% CI 0.200.44) and LNM risk in gastrointestinal cancer (OR = 0.55, 95% CI 0.320.95) (Fig. 4c, d).

**Publication bias**
Publication bias was measured for studies reporting OS by using the funnel plot, Begg’s and Egger’s test. No significant publication bias was observed as the funnel plot showed symmetry, as demonstrated in Fig. 4e. Moreover, the P values for Begg’s and Egger’s test were 0.533 and 0.111, respectively, also indicating the absence of publication bias.
Furthermore, the relationships between expression of MIR31HG and OS/DFS in lung cancers were validated in TCGA and GTEx dataset by using GEPIA as previously described [11]. The results indicated that high MIR31HG expression was correlated with significant shorter OS (HR = 1.3, \( P = 0.012 \)), but not DFS (HR = 0.99, \( P = 0.96 \)) (Fig. 5). Besides, the aberrant expression pattern of MIR31HG in multiples cancers and matched normal tissues were also identified, including sarcoma (SARC), LUAD, lung squamous cell carcinoma (LUSC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), pancreatic adenocarcinoma (PAAD), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and esophageal carcinoma (ESCA) (Additional file 1: Figure S1b, c).

**Discussion**

Identifying correlative biomarkers with high sensitivity and specificity is of great importance in cancer diagnosis and treatment [5]. Recently, with the development of next generation sequencing, lncRNAs are revealed as multifaceted regulators in a wide range of cellular homeostasis [37] via participating in epigenetic, transcriptional and posttranscriptional regulation of genes [26]. Increasing evidences have established a strong relationship between dysfunction of lncRNAs and cell fate determination as well as disease pathogenesis, such as aging [38], arthritis [39], and cancer [13]. LncRNA MIR31HG, locating at human chromosome 9p21.3 [40] with transcription regulated by methylation of the promoter region [27], was found aberrantly expressed in several types of cancers. Specifically, MIR31HG was found elevated expressed in breast cancer [13], cervical cancer [28], chordoma [16], osteosarcoma [15], lung cancer [2, 23, 41], OSCC [4], PDAC [7], VSCC [29] and LSCC [36, 42, 43]. Nevertheless, the expression levels of MIR31HG was reported down-regulated in triple-negative breast cancer (TNBC) cell lines of basal subtype [27], bladder cancer [26], gastric cancer [25], CRC [32, 33], and HCC [6]. Besides, abnormal expression of MIR31HG was deemed as potential biomarker to reflect the clinicopathological characteristics and prognostic outcomes of cancer patients [28]. For instance, increased MIR31HG expression was found both in LUAD/NSCLC tissues when compared with counterparts, and positively associated with unfavorable TNM stage, metastasis, histological differentiated degree, and forecasted shorter OS [2, 23, 41]. Notably, MIR31HG expression was even higher in gefitinib-resistant NSCLC cells, and knockdown of MIR31HG could promote cell apoptosis and cell cycle arrest, and subsequently induce gefitinib sensitivity [20]. More recently, He J et al. further verified that MIR31HG was also remarkably increased in gefitinib-resistant NSCLC patients, and MIR31HG overexpression

| Authors          | Publication year | Country | Cancer type          | Sample size | Follow-up months | Detection method | Clinical outcomes | Analysis method | NOS |
|------------------|------------------|---------|----------------------|-------------|------------------|------------------|------------------|----------------|-----|
| Chen et al. [27] | 2017             | China   | Cervical cancer      | 120         | 60               | qRT-PCR          | OS               | Multivariate    | 7   |
| Ding et al. [18] | 2015             | China   | CRC                  | 48          | –                | qRT-PCR          | –                | Multivariate    | 6   |
| Eide et al. [16] | 2019             | Norway  | CRC                  | 1265        | 60               | qRT-PCR          | RFS              | Multivariate    | 7   |
| He et al. [25]   | 2016             | China   | Bladder cancer       | 55          | –                | qRT-PCR          | –                | Multivariate    | 6   |
| Li et al. [31]   | 2018             | China   | CRC                  | 157         | 100              | qRT-PCR          | OS, DFS          | Multivariate    | 7   |
| Ni et al. [28]   | 2016             | China   | VSCC                 | 16          | –                | qRT-PCR          | –                | Multivariate    | 6   |
| Nie et al. [24]  | 2016             | China   | Gastric cancer       | 42          | 40               | qRT-PCR          | OS               | Multivariate    | 6   |
| Qin et al. [22]  | 2018             | China   | LUAD                 | 122         | 85               | qRT-PCR          | OS               | Multivariate    | 7   |
| Ren et al. [30]  | 2017             | China   | ESCC                 | 185         | 60               | qRT-PCR          | OS               | Multivariate    | 6   |
| Shih et al. [4]  | 2017             | China   | OSCC                 | 42          | 40               | RNA-seq          | OS, RFS          | Multivariate    | 7   |
| Sun et al. [29]  | 2018             | China   | ESCC                 | 53          | –                | qRT-PCR          | –                | Multivariate    | 6   |
| Sun et al. [14]  | 2019             | China   | Osteosarcoma         | 40          | –                | qRT-PCR          | –                | Multivariate    | 6   |
| Wang et al. [35] | 2018             | China   | LSCC                 | 60          | 85               | qRT-PCR          | OS, DFS          | Multivariate    | 7   |
| Wu et al. [40]   | 2019             | China   | NSCLC                | 50          | 85               | qRT-PCR          | OS               | Multivariate    | 8   |
| Yan et al. [5]   | 2018             | China   | HCC                  | 42          | 25               | qRT-PCR          | OS               | Multivariate    | 7   |
| Yang et al. [32] | 2016             | China   | CRC                  | 178         | 70               | qRT-PCR          | OS, DFS          | Multivariate    | 7   |
| Zheng et al. [2] | 2019             | China   | NSCLC                | 88          | 50               | qRT-PCR          | OS               | Multivariate    | 8   |

CRC colorectal cancer, DFS disease-free survival, ESCC esophageal squamous cell carcinoma, HCC hepatocellular carcinoma, LSCC laryngeal squamous cell cancer, LUAD lung adenocarcinoma, NOS Newcastle-Ottawa Scale, NSCLC Non–small cell lung cancer, OS overall survival, OSCC oral squamous cell carcinoma, qRT-PCR real-time quantitative reverse transcription polymerase chain reaction, RFS relapse-free survival, VSCC vulvar squamous cell carcinoma
Fig. 2 Forest plots describing the overall and subgroup analysis of HRs for association between MIR31HG expression and OS (a), DFS (b), and RFS (c). CI confidence interval, DFS disease-free survival, HR hazard ratio, OS overall survival, RFS relapse-free survival.
Table 2 The pooled results of association between clinical prognosis and MIR31HG expression

| Outcomes | Studies | Participants | HRs and 95% CIs | Model | Heterogeneity p, I² |
|----------|---------|--------------|----------------|-------|--------------------|
| OS       | 11      | 1096         | 1.10 (0.60, 2.03) | Random | < 0.001, 88.1%     |
| Gastrointestinal cancer | 5      | 604          | 0.56 (0.41, 0.77) | Random | 0.825, 0%          |
| Lung cancer | 3      | 270          | 1.64 (1.15, 2.34) | Random | 0.615, 0%          |
| Other cancers | 3     | 222          | 3.37 (2.69, 4.23) | Random | 0.746, 0%          |
| DFS      | 2       | 335          | 0.44 (0.27, 0.72) | Fixed  | 0.551, 0%          |
| RFS      | 3       | 1367         | 2.54 (1.91, 3.38) | Fixed  | 0.610, 0%          |

CI confidence interval, DFS disease-free survival, HR hazard ratio, OS overall survival, RFS relapse-free survival

Fig. 3 Forest plot describing overall and stratified analysis of relationship between MIR31HG expression and clinicopathological parameters, including DM (a), tumor size (b), advanced clinical stage (c), and LNM (d). DM distant metastasis, LNM lymph node metastasis
contributed to reduced sensitivity of NSCLC cell to gefitinib in vitro [44]. By contrast, Yan S et al. reported that overexpression of MIR31HG significantly inhibited HCC proliferation and metastasis in vitro and impeded tumorigenesis in vivo [6]. In CRC, the MIR31HG expression was negatively correlated with unfavorable prognosis, as indicated by advanced pathologic stage, and larger tumor size [19]. Consistently, Li Y et al. found that high expression of MIR31HG predict high OS and DFS in CRC patients treated with oxaliplatin [32].

Fig. 4 Sensitivity analysis of each study reporting clinical stages (a) and LNM (b). Overall and subgroup analysis of association between MIR31HG expression and advanced clinical stage (c), or LNM (d) after deletion according to the sensitive analysis. Begg’s funnel plot for included studies reporting OS (e) LNM lymph node metastasis, OS overall survival
Given the prognostic significance of MIR31HG in cancers, in the current study, we firstly explored the association between MIR31HG level and clinical outcomes by performing a meta-analysis containing seventeen literatures with 2573 patients. The pooled results of subgroup analysis as per the tumor types demonstrated that high MIR31HG expression predicted unfavorable OS in patients with lung cancer and other cancers, and poor RFS in all selected studies, respectively. On the contrary, overexpression of MIR31HG was closely associated with favorable OS and DFS in gastrointestinal cancer, indicating a tissue-specific predictive prognosis of MIR31HG in multiple human cancers. Besides, the relationship between expression of MIR31HG and other parameters were analyzed. Consistent with the predictive value of MIR31HG in OS, high level of MIR31HG was also significantly correlated with advanced clinical stage and LNM potential in lung cancer. Previously, the remarkable associations between MIR31HG expressions with LNM risk or tumor stage in gastrointestinal cancer were not noted. However, we found that the study performed by Sun et al. may introduce bias to this meta-analysis, as shown in sensitivity analysis. Therefore, in order to increase the stability of the results, we excluded this study and found that elevated expression of MIR31HG were negatively associated with clinical stage and LNM risk in gastrointestinal cancer. However, no correlation between MIR31HG expression and other clinical characteristics, such as DM and tumor size, were noted. It is worth mentioning that since the studies with regard to the relationship between expression of MIR31HG and other clinical parameters are limited, these results could be biased and therefore needs further confirmation in future studies. Beside, in order to increase the credibility of the results, we performed cross-validation of the results by using TCGA dataset. The results showed the elevated MIR31HG was significantly correlated with poor OS rather than DFS in lung cancer. However, it should be noted that the enrolled studies reporting MIR31HG expression in lung cancers consisted of LUAD and NSCLC, while the cancer types in TCGA were LUAD and LUSC, which may lead to potential difference in predictive value of MIR31HG on clinical outcomes between this meta-analysis and TCGA dataset. Moreover, the limited sample size in TCGA may cause possible bias to the results.

Mechanistically, lncRNA could execute versatile functions in diseases through alternative splicing, epigenetic modulation, chromatin modification, scaffolding/decoy function or acting as molecular sponge [45]. To begin with, given the critical role of MIR31HG in hypoxia-associated malignant progression, MIR31HG was observed to promote tumorigenesis by serving as a HIF-1α co-activator and regulating HIF-1 transcriptional network [4, 42]. For instance, in LSCC, MIR31HG could facilitate cell proliferation, cell cycle progression and suppress apoptosis via HIF-1α and p21 [36]. In OSCC, MIR31HG knockdown impaired the HIF-1α transactivation, spheroid-forming ability, metabolic shift and metastatic cascade both in vitro and in vivo [4]. Besides, lncRNA could involve in the competing endogenous RNA (ceRNA) regulatory work to function as endogenous miRNA sponge (Table 3) [6]. As the host gene of miR-31, MIR31HG was firstly identified to co-express or modulate the expression of miR-31 in certain cancers [44]. For example,
MIR31HG could enhance proliferation, migration and invasion by up-regulating EZH2/miR-31 and then indirectly activating the oncogene RNF144B in chordoma [15]. Yang et al. demonstrated that elevated MIR31HG could inhibit miR-31 expression, and increase RhoA in LSCC, and via which promote cell growth, cell cycle and invasion [42]. In addition to miR-31, other miRNAs were also identified to interact with MIR31HG in carcinogenesis. It was reported that MIR31HG could directly sponge to tumor suppressor- miR-361, rather than miR-31, and in turn regulate cell proliferation, cell cycle arrest, and apoptosis via targeting VEGF, FOXM1 and Twist in osteosarcoma [15]. In NSCLC, MIR31HG behaved as an oncogene by inhibiting miR-214 expression, thereby facilitating cancer cell migration and invasion [41]. In HCC cancer, MIR31HG could competitively bind miR-575, and positively regulate ST7L to impair cell proliferation and metastasis [6]. Moreover, MIR31HG could regulate tumorigenesis by targeting a broad spectrum of target genes or pivotal signaling pathways (Table 3). In gastric cancer, MIR31HG may suppress cell proliferation and hinder tumorigenesis partly by regulation of E2F1 and p21 expression [25]. In NSCLC, MIR31HG was found to enhance Wnt/β-catenin pathway, and induce

| Tumor type     | Expression | Signaling pathways | MiRNAs and target genes | Biological functions                                                                 | References |
|----------------|------------|--------------------|-------------------------|-------------------------------------------------------------------------------------|------------|
| Osteosarcoma   | ↑          | /                  | miR-361, VEGF, FOXM1, Twist | Cell proliferation, migration, apoptosis, G1/G arrest, EMT                            | [14]       |
| Chordoma       | ↑          | /                  | miR-31, EZH2, RNF144B    | Cell proliferation, migration, invasion, EMT                                         | [15]       |
| OSCC           | ↑          | /                  | HIF-1α, p300             | Sphere-forming ability, metabolic shift and metastasis                               | [4]        |
| HNSCC/LSCC     | ↑          | /                  | HIF-1α, p21              | Cell proliferation, cell cycle progression, apoptosis                                | [35]       |
| LSCC           | ↑          | /                  | miR-31, RhoA             | Cell growth, cell cycle, invasion                                                   | [42]       |
| Breast cancer  | ↑          | /                  | /                       | Cell proliferation, apoptosis, migration, invasion                                   | [12]       |
| Cervical cancer| ↑          | /                  | /                       | Cell proliferation, apoptosis                                                       | [27]       |
| VSCC           | ↑          | /                  | /                       | /                                                                                   | [28]       |
| NSCLC          | ↑          | /                  | miR-31, FIH-1, RASA1     | Cell proliferation, clonogenic growth, gefitinib resistance                          | [43]       |
| LUAD           | ↑          | /                  | miR-214                  | Cell migration, invasion                                                            | [40]       |
| PDAC           | ↑          | /                  | miR-193b, CCND1, Mcl-1, NTSE, KRAS, uPA, ETS1 | Cell proliferation, cell cycle arrest                                               | [22]       |
| ESCL           | ↑          | /                  | Furin, MMP1              | Cell proliferation, migration, invasion                                              | [29]       |
| ESCC           | ↑          | /                  | /                       | /                                                                                   | [30]       |
| Gastric cancer | ↑          | /                  | p21, E-cadherin          | Cell proliferation, migration                                                        | [33]       |
| Gastric cancer | ↑          | /                  | E2F1                     | Cell proliferation                                                                  | [24]       |
| CRC            | ↑          | /                  | miR-31-5p, MYC, TNF-α/NF-κB, TGF-β, IFN-α/γ | Cell proliferation, clonogenic growth, gefitinib resistance                        | [16]       |
| CRC            | ↓          | /                  | /                       | /                                                                                   |            |
| HCC            | ↓          | /                  | miR-575, ST7L            | Cell proliferation, apoptosis                                                        | [18]       |
| Bladder cancer | ↓          | /                  | /                       | /                                                                                   | [25]       |

↑up-regulated, ↓down-regulated
epithelial-mesenchymal transition (EMT) phenotype [2]. Jin et al. identified that MIR31HG was induced by nuclear translocation of NF-κB, and in turn directly bind to IκBα and participated in NF-κB activation, revealing an interaction between MIR31HG and NF-κB in osteogenic differentiation [46]. Of note, MIR31HG could modulate gefitinib resistance partly through EGFR/Pi3K/Akt [20, 44] or RAF-MEK-ERK pathways [44]. Furthermore, Zheng S and colleagues discovered that down-regulation of MIR31HG inhibited NSCLC cell proliferation, invasion and EMT phenotype via up-regulating E-cadherin expression, inhibiting Wnt/β-catenin cascade, and down-regulating expression of Twist1 and vimentin [2].

Despite an effort to make a comprehensive analysis, limitations remained inevitably in this study. First, most of the studies were among Asian populations though we do not impose restrictions on region during literature retrieval, which may introduce possible geographical bias. However, since these results have been further confirmed by TCGA dataset [21], it could be more credible to generalize the data to other populations. Second, some HRs with corresponding 95% CIs were indirectly extracted from the Kaplan–Meier (K-M) survival curves, which may introduce possible bias. Third, the cut-off value of MIR31HG levels varied among the selected studies, which may contribute to potential limitation to the clinical use.

Conclusion
Taken together, our study provided evidence that MIR31HG overexpression suggested remarkable association with poor prognosis in terms of OS, tumor stage, and LNM in lung cancer, but favorable prognosis in gastrointestinal cancer. Therefore, MIR31HG may serve as a novel promising prognostic biomarker in patients with multiple cancers. However, more rigorously designed prospective studies with large sample size and complete clinical information are still requested for further confirmation of the results.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01194-y.

Additional file 1: Figure S1. Forest plots describing subgroup analysis of HRs for association between MIR31HG expression and OS based on follow-up months (a) and expression pattern of MIR31HG in cancerous tissues and matched normal samples in various cancers (b, c). CI: confidence interval, HR hazard ratio, OS overall survival.

Abbreviations
Akt: Protein kinase B; BCAR4: Breast cancer anti-estrogen resistance 4; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CCND1: Cyclin D1; ceRNA: Competing endogenous RNA; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CI: Confidence interval; COAD:

Colon adenocarcinoma; CRC: Colorectal cancer; DFS: Disease-free survival; DM: Distant metastasis; E2F1: E2F transcription factor 1; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; ERK: Extracellular regulated protein kinases; ESCA: Esophageal carcinoma; ESCC: Esophageal squamous cell carcinoma; ETS1: Ets proto-oncogene 1, transcription factor; E2H2: Enhancer of zeste 2 polycomb repressive complex 2 subunit; FIGO: FOXM1: forkhead box M1; GEPIA: Gene Expression Profiling Interactive Analysis; GSK-3B: Glycogen synthase kinase-3B; HCC: Hepatocellular carcinoma; HIF-1α: Hypoxia inducible factor 1 subunit alpha; HNSCC: Head and neck squamous cell carcinoma; HR: Hazard ratio; IFN-α/γ: Interferon-α/γ; K-M: Kaplan–Meier; IncRNA: Long non-coding RNA; LncHIFCAR: Long noncoding HIF-1α co-activating RNA; LNM: Lymph node metastasis; LSCC: Laryngeal squamous cell cancer; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MIR13HG: MicroRNA-31 host gene; MMP1: Matrix metalloproteinase 1; NOS: Newcastle–Ottawa Scale; NSCLC: Non-small cell lung cancer; NTSE: S′-Nucleotidase ecto; OS: Overall survival; OSCC: Oral squamous cell carcinoma; PAAD: Pancreatic adenocarcinoma; PDAC: Pancreatic ductal adenocarcinoma; PFS: Progression-free survival; PI3K: Phosphoinositide 3-kinase; qRT-PCR: Real-time quantitative reverse transcription polymerase chain reaction; READ: Rectum adenocarcinoma; RFS: Relapse-free survival; RhoA: Ras homolog gene family, member A; SARC: Sarcoma; SNHG16: Small nuclear RNA host gene 16; ST7L: Suppression of tumorigenicity 7 like; STAD: Stomach adenocarcinoma; TCGA: The Cancer Genome Atlas; TGF-β: Transforming growth factor-β; TTN-AS1: TTN antisense RNA 1; TNF: Tumor necrosis factor; VEGF: Vascular endothelial growth factor; VSCC: Vulvar squamous cell carcinoma.

Acknowledgements
We would like to thank the researchers and study participants for their contributions.

Authors’ contributions
CT and ZHL conceptualized the study and designed the methodology of the study. CT and XLR performed the literature retrieval, data analysis and interpretation. JYH and SQL participated in the quality assessment, and assisted in the statistical analysis. LQ and ZXD participated in the data analysis, and assisted in creating the figures. WCW participated in the data interpretation and assisted in manuscript drafting. ZHL and WCW critically reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81902745), Natural Science Foundation of Hunan Province, China (2018JJ3716, 2018JJ3762), China Scholarship Council (201806375067, 201806375068), and the Fundamental Research Funds for the Central Universities of Central South University (2017zzts231).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests in this work.

Author details
1 Department of Orthopedics, The Second Xiangya Hospital, Central South University, No 139 Middle Renmin Road, Changsha, Hunan 410011, China. 2 Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China. 3 Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.

Received: 3 February 2020 Accepted: 27 March 2020
Published online: 07 April 2020
1. Wu Y, Hou Y, Xu P, Deng Y, Liu K, Wang M, et al. The prognostic value of YAP1 on clinical outcomes in human cancers. Aging. 2019;11(19):8681–700.

2. Zheng S, Zhang X, Wang X, Li J. MIR31HG promotes cell proliferation and invasion by activating the Wnt/beta-catenin signaling pathway in non-small cell lung cancer. Onco Lett. 2019;17(1):221–9.

3. Huo X, Han S, Wu G, Latchoumanin O, Zhou G, Hebbard L, et al. Dys-regulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cell. Mol Cancer. 2017;16(1):165.

4. Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, et al. The prognostic value of long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun. 2017;8:15874.

5. Zhang Y, He W, Zhang S. Seeking for correlative genes and signaling pathways with bone metastasis from breast cancer by integrated analysis. Front Oncol. 2019;9:138.

6. Yan S, Tang Z, Chen K, Liu Y, Yu G, Chen Q, et al. Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression. J Exp Clin Cancer Res. 2018;37(1):214.

7. Yuan Y, Liu P, Zheng J, Peng X, Lu Z, Yu S, et al. Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b. Oncogene. 2016;35(28):3647–57.

8. Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNA. Annu Rev Immunol. 2017;35:177–98.

9. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–63.

10. Tu C, Ren X, He J, Zhang C, Chen R, Wang W, et al. The value of LncRNA BCAAR4 as a prognostic biomarker on clinical outcomes in human cancers. J Cancer. 2019;10(24):5992–6002.

11. Zhang C, Ren X, He J, Wang W, Tu C, Li Z. The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis. Cancer Cell Int. 2019;19:261.

12. Fu D, Lu C, Qu X, Li P, Chen K, Shan L, et al. LncRNA TNT-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBD1 axis. Aging. 2019;11(19):8374–85.

13. Shi Y, Lu J, Zhou J, Tan X, He Y, Ding J, et al. Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. Biochem Biophys Res Commun. 2014;446(2):448–53.

14. Montes M, Nielsen MW, Magni G, Jacobsen A, Hoffeldt J, Agrawal-Singh S, et al. The lncRNA MIR31HG regulates p16INK4A to modulate senescence. Nat Commun. 2015;6:9687.

15. Sun Y, Jia X, Wang M, Deng Y. Long noncoding RNA MIR31HG abrogates the availability of tumor suppressor microRNA-361 for the growth of osteosarcoma. Cancer Manag Res. 2019;11:8053–64.

16. Ma X, Qi S, Duan Z, Liao H, Yang B, Wang W, et al. Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression. Cell Prolif. 2017;50(6).

17. Eide PW, Eilertsen IA, Sveen A, Lothe RA. Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b. Oncogene. 2016;35(28):3647–57.

18. Augoff K, McBeue B, Plow EF, Sossey-Alaoui K, MIR31-1 and its host gene LncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer. 2012;11:5.

19. Sun K, Zhao X, Ouyang L. Long non-coding RNA expression profile in vulvar squamous cell carcinoma and its clinical significance. Oncol Rep. 2016;36(5):2571–8.

20. Liu B, Chen Y, Yang J. LncRNAs are altered in lung squamous cell carcinoma for identification of a potential biomarker. Tumour Biol. 2016;37(6):7693–701.

21. He A, Chen Z, Mei H, Liu Y. Decreased expression of LncRNA MIR31HG in human bladder cancer. Cancer Biomark. 2016;17(2):251–6.

22. Ning P, Wu Z, Hu A, Li X, He J, Gong X, et al. Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. Peer J. 2018;6:e4254.
46. Jin C, Jia L, Huang Y, Zheng Y, Du N, Liu Y, et al. Inhibition of IncRNA MIR31HG promotes osteogenic differentiation of human adipose-derived stem cells. Stem Cells. 2016;34(11):2707–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.